- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06155006
Adult Screening for Hepatitis c and Linkage to Treatment in Hospitals in Colombia (HCVLINKAGE)
Introduction: Hepatitis C virus infection is a major cause of chronic hepatitis, cirrhosis, and liver cancer. The risk of developing cirrhosis for people with chronic infection with the virus ranges from 15% to 30% over a 20-year period. According to 2019 data from the World Health Organization there are 58 million people living with chronic hepatitis C infection. Three-quarters of those infected live in low- to middle-income countries, some of which lack budgets for screening, diagnosis and treatment campaigns. While good progress has been made in several countries, a significant gap in testing and treatment remains. Barriers to timely diagnosis include lack of awareness on the part of health professionals, availability and access to screening tests. Simplifying the cascade of care for this pathology would help ensure that more patients remain involved in the care pathway and ultimately achieve global goals.
Objective: To estimate the prevalence of anti-HCV antibodies in patients with risk factors for hepatitis C virus captured by opportunity screening in the included hospital institutions.
Methodology: Descriptive multicenter cross-sectional study. A total of 27160 participants among the seven institutions, 3880 per institution. Includes all persons over 18 years of age attended in the included health service provider institutions (IPS) who are users of hospitalization, emergency, outpatient and any other hospital care services. Application of a questionnaire to identify the inclusion criteria and data collection, signature of informed consent, sample collection by rapid test Abbott HCV rapid test - BIOLINE HCV and evaluation by tele-consultation by hepatologist principal investigator who will guide you to access the confirmatory test for HCV (viral load for Hepatitis C), the study will assume responsibility for its realization.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Research question
¿What is the prevalence of HCV in the population with risk factors for hepatitis C virus infection captured by screening with rapid tests in health care institutions in Colombia?
Through this observational, multicenter, hospital population study, the prevalence will be determined by screening patients with risk factors for hepatitis C by rapid antibody test, to subsequently perform confirmation with viral load PCR in those seropositive. In addition, support will be provided to patients to facilitate their treatment adherence.
The benefits would be related to raising awareness of the importance of the active search for these patients, reducing the health impact for the screened population, incorporating these strategies in the country's hospital institutions, and obtaining epidemiological information that helps to understand the magnitude of the disease and the opportunity for its elimination.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Javier Hernández Blanco, DR
- Phone Number: +57 318 3483581
- Email: jhernandezblanco@gmail.com
Study Contact Backup
- Name: Diana Chávez Bejarano, Dra
- Phone Number: +57 3124541333
- Email: dianachavezbejarano@outlook.com
Study Locations
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050001
- Hospital Pablo Tobon Uribe
-
Contact:
- Juan Ignacio Marín Zuluaga, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Have at least one of the following risk factors for hepatitis C.
- Over 50 years of age with no risk factors.
- Over 18 years old and less than 50 years old with risk factors for hepatitis C. Persons who have received medical or dental interventions in health care settings.
Persons who have had tattoos, body piercings, or scarification procedures. Persons with HIV or hepatitis B infection. Persons who inject drugs. Persons who have used intranasal drugs. Persons deprived of liberty and previously incarcerated persons. Anyone with abnormal liver tests or liver disease. Students, health care workers, or members of public safety (e.g. correctional service officers or police) who have come into contact with blood at work through needlestick or sharps injuries. Anyone who has undergone hemodialysis. Persons who received transfusions in Colombia before 1996. Persons with comorbidities potentially associated with CH: diabetes, ischemic heart disease, cryoglobulinemia, chronic renal failure, Sjögren's syndrome, hypothyroidism, lichen planus, rheumatoid arthritis, HIV, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, waldenstrom's macroglobulinemia.
- Individuals previously treated for HCV with sustained viral response in whom reinfection is suspected (individuals who continue to engage in risk behaviors)
- Accept to participate in the study by signing the informed consent form.
Exclusion Criteria:
- Have or have had hepatitis C with a proven cure by viral load at 12 weeks after the end of treatment without risk behaviors for reinfection.
- Be on antiviral treatment against chronic hepatitis C virus.
- That the patient voluntarily and consciously refuses to sign the informed consent form or is unable to give it due to any type of physical and/or mental disability.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Adults with risk factors for hepatitis C virus
All persons over 18 years of age who are treated in the included health care institutions (IPS) and who are users of hospitalization, emergency, outpatient, and any other hospital care services.
|
The sample will be taken by trained personnel by capillary puncture of the thumb region of the fingers of the right hand, after asepsis and antisepsis, the rapid diagnostic test HCV Ab Plus Rapid test with INVIMA registration 2018RD-0002353-R1 will be used with operational characteristics that allow its performance at the point of care obtaining a result in 15 to 20 minutes.
This rapid test for antibodies against HCV may be replaced by another test with similar operational characteristics (sensitivity and specificity).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence
Time Frame: 12 months
|
Hepatitis C virus prevalence
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opportunity for treatment
Time Frame: 12 months
|
Access to treatment for hepatitis C virus infection
|
12 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CO-US-987
- CO-US-987-6934 (Other Grant/Funding Number: Colombian Association of Hepatology)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Informed consent will be requested in written form to all participants, giving clear and easily understandable information about the objectives of the research. The consent will be explained and doubts about it will be resolved and complete freedom of withdrawal of consent will be given at any time during the study, for the reasons that the subject considers.
The study will be coordinated by health professionals and the sampling and data collection will be performed by nursing assistants trained in rapid tests. The confidentiality of the data collected will be guaranteed, the information obtained will not be used for purposes other than the current research process, and sensitive data or data that allow the identification of the participating individuals will not be published when the information is disclosed.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C Virus Infection
-
University Health Network, TorontoCompletedChronic Hepatitis C Virus InfectionCanada
-
PharmaEssentiaCompletedChronic Hepatitis C Virus InfectionKorea, Republic of, Taiwan, China
-
Gilead SciencesCompleted
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
-
Bristol-Myers SquibbCompletedChronic Hepatitis C Virus Infection | Chronic Hepatitis B Virus InfectionUnited States
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
Vertex Pharmaceuticals IncorporatedTerminatedChronic Hepatitis C Virus InfectionUnited States, New Zealand
Clinical Trials on rapid diagnostic test HCV Ab Plus Rapid test
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; Fondation... and other collaboratorsUnknown
-
Hospital Universitario Infanta LeonorCompletedHIV Infections | Drug Use | HCV Infection | HBV (Hepatitis B Virus) | Viral HepatitisSpain
-
Abbott Rapid DxBill and Melinda Gates FoundationCompleted
-
London School of Hygiene and Tropical MedicineHealthNet TPO; Health Protection and Research Organisation; Medical Emergency...CompletedFever | MalariaAfghanistan
-
London School of Hygiene and Tropical MedicineHealthNet TPO; Health Protection and Research Organisation; Medical Emergency...CompletedPneumonia | Fever | Malaria | Acute Febrile IllnessAfghanistan
-
Foundation for Innovative New Diagnostics, SwitzerlandUniversity of Khartoum; Eijkman Institute for Molecular BiologyCompletedMalaria | Diagnoses Disease | RDTSudan, Indonesia
-
Foundation for Innovative New Diagnostics, SwitzerlandUniversity of Khartoum; Universidad Peruana Cayetano Heredia; Eijkman Institute...CompletedMalaria | Diagnoses Disease | RDTIndonesia, Peru, Sudan
-
London School of Hygiene and Tropical MedicineKilimanjaro Christian Medical Centre, TanzaniaCompletedMalaria | Febrile IllnessTanzania
-
Montefiore Medical CenterEmory University; National Institutes of Health (NIH); Unity Health Care, Inc.Completed
-
CMC Ambroise ParéTerminatedCOVID-19 | SARS-CoV-2France